Insmed Incorporated (INSM) Receives Average Rating of “Buy” from Brokerages

Shares of Insmed Incorporated (NASDAQ:INSM) have earned an average rating of “Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $37.00.

A number of research analysts recently weighed in on INSM shares. Morgan Stanley raised their price objective on Insmed from $39.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, October 1st. Goldman Sachs Group set a $25.00 price objective on Insmed and gave the company a “hold” rating in a research report on Wednesday, September 19th. Credit Suisse Group raised their price objective on Insmed from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, October 1st. ValuEngine lowered Insmed from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 4th. Finally, BidaskClub raised Insmed from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 27th.

INSM opened at $17.14 on Monday. The company has a market capitalization of $1.31 billion, a PE ratio of -5.93 and a beta of 1.73. The company has a debt-to-equity ratio of 1.07, a current ratio of 10.06 and a quick ratio of 10.06. Insmed has a 52 week low of $13.85 and a 52 week high of $33.94.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.06) by ($0.08). As a group, research analysts expect that Insmed will post -4.11 earnings per share for the current fiscal year.

In other Insmed news, Director Steinar J. Engelsen bought 16,085 shares of Insmed stock in a transaction on Thursday, November 1st. The stock was acquired at an average price of $15.79 per share, with a total value of $253,982.15. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Melvin Md Sharoky bought 8,795 shares of Insmed stock in a transaction on Monday, November 12th. The stock was acquired at an average cost of $15.59 per share, with a total value of $137,114.05. Following the acquisition, the director now owns 231,794 shares in the company, valued at approximately $3,613,668.46. The disclosure for this purchase can be found here. In the last three months, insiders acquired 54,785 shares of company stock valued at $871,726. Corporate insiders own 3.88% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. NumerixS Investment Technologies Inc bought a new stake in shares of Insmed in the 2nd quarter worth $122,000. Pacer Advisors Inc. bought a new stake in shares of Insmed in the 3rd quarter worth $155,000. Cubist Systematic Strategies LLC bought a new stake in shares of Insmed in the 2nd quarter worth $200,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Insmed in the 2nd quarter worth $200,000. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Insmed in the 3rd quarter worth $452,000.

Insmed Company Profile

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.

Featured Article: Day Trading

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply